Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Selinexor in Combination with Pomalidomide and Dexamethasone for Treatment of Patients with RRMM

Conference Correspondent  - ASH Highlights

Selinexor (SEL) is a novel, first-in-class, oral selective inhibitor of nuclear export. SEL blocks XPO1, forcing the nuclear retention and activation of tumor suppressor proteins, subsequently causing apoptosis in cancer cells. The hypothesis of this study was that the addition of once-weekly SEL to pomalidomide (POM) + dexamethasone (dex; SPd) would demonstrate improved activity and acceptable tolerability when compared with POM + dex alone.

STOMP is a multicenter, open-label phase 1b/2, dose-escalation study with an expansion phase. Patients were eligible if they had relapsed/refractory multiple myeloma (RRMM) and had received ≥2 prior therapies, including lenalidomide and a proteasome inhibitor in either separate or the same regimens. SEL was evaluated in 28-day cycles, using 2 different dosing schedules (once-weekly 60, 80, or 100 mg or twice-weekly 60 or 80 mg), with escalating doses of POM 2 mg, 3 mg, or 4 mg (days 1-21), and dex 20 mg twice weekly or 40 mg once weekly. This study had 2 primary objectives. The first was to determine the maximum tolerated dose and the recommended phase 2 dose. The second was to assess the safety, tolerability, overall response rate (ORR), and progression-free survival (PFS) of SPd in patients with RRMM.

A total of 65 patients were enrolled. The median age was 64 years (range, 37-85 years). Patients received a median of 3 (range, 1-10) prior therapies, including 47 (72.3%) with autologous stem-cell transplantation. During the escalation phase, 6 dose-limiting toxicities were noted. Common hematologic treatment-related adverse events (TRAEs) included (all grades; grade ≥3) neutropenia (60.3%; 54.0%), anemia (54%; 33.3%), thrombocytopenia (54%; 31.7%), and leukopenia (23.8%; 12.7%). Common nonhematologic TRAEs (all grades; grade ≥3) included nausea (60.3%; 1.6%), fatigue (50.8%; 9.5%), decreased appetite (44.4%; 1.6%), weight loss (38.1%; 0%), diarrhea (28.6%; 0%), and vomiting (20.6%; 1.6%). Following a review of all the safety data, the recommended phase 2 dose was SEL 60 mg once weekly, POM 4 mg (days 1-21), and dex 40 mg once weekly.

Sixty of the 65 patients were evaluable for response. Among POM-naïve patients (n = 46), the ORR was 54.3% (1 complete response, 9 very good partial responses [VGPRs], and 15 partial responses [PRs]). For this group, the median PFS was 12.3 months and the median overall survival was 19.0 months. The ORR for patients who previously received POM was 35.7% (1 VGPR and 4 PRs). The mean PFS for all patients was 12.2 months, and the duration of response was 11.3 months.

In conclusion, the recommended phase 3 dose is SEL 60 mg once weekly, POM 4 mg once daily, and dex 40 mg once weekly. All TRAEs were expected and manageable with appropriate supportive care (eg, administration of granulocyte colony-stimulating factor for neutropenia) and/or dose modifications. The combination of SPd appears to offer relatively high ORRs, with good durability and encouraging PFS in heavily pretreated patients with multiple myeloma.


Reference

Abstract 726. ASH 2020. December 7, 2020. Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM).

Related Items
Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelodysplastic Syndromes
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Graft-versus-Host-Disease
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Clinical Trials, Lymphoma
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, CAR T-Cell Therapy, Lymphoma
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelofibrosis, Novel Pharmaceuticals
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Leukemia, Novel Pharmaceuticals
A Phase 2 Study of Isatuximab for Patients with Previously Treated AL Amyloidosis
Conference Correspondent  published on December 9, 2020 in ASH Highlights
VRD Consolidation Followed by Lenalidomide Maintenance versus Maintenance Alone in Transplant-Eligible Patients with NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
A Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Phase 2 GRIFFIN Study Update: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.